A new opportunity in ovarian cancer treatment

Czech version

Authors: I. Sedláková
Authors‘ workplace: Porodnická a gynekologická klinika LF UK a FN, Hradec Králové, přednosta doc. MUDr. J. Tošner, CSc.
Published in: Ceska Gynekol 2012; 77(5): 469-471

Overview

Objective:
Targeted treatment in ovarian cancer patients.

Design:
Practical paper.

Setting:
Department of Gynecology and Obstetrics, Medical Faculty Charles University, Prague and University Hospital, Hradec Králové.

Conclusion:
Targeted treatment is possible based on particular characteristics of single tumors in ovarian cancer patients. Better understanding of tumor biology should contribute to predict certain patients would benefit most from use of targeted treatment.

Key words:
ovarian cancer, VEGF, bevacizumab, targeted treatment.

Sources

1. Bast, RC. Jr. Biomarkers for ovarian cancer: New technologies and targets to adress persistently unmet needs. Cancer Biomarkers, 2011, 8, p. 161–166.

2. Burger, RA., Brady, MF., Bookman, MA., et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or Fallopian tube cancer (FTC): a gynecologic oncology group study. Oral presentation at: the 46^th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL, USA, 2010.

3. Eskander, RN., Randall, LM. Bevacizumab in the treatment of ovarian cancer. Biologics, 2011, 5, p. 1–5.

4. Hamburg, MA. Department of Health and Human Services Food and Drug Administration. Decision of the Commissioner. Proposal to withdraw approval for the breast cancer indication for Avastin (Bevacizumab). Docket No. FDA-2010-N-0621.

5. Muggia, FM., Braly, PS., Brady, MF., et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol, 2000, 18, p. 106–115.

6. Pollack, A. F.D.A. revokes approval of Avastin for use as breast cancer drug. The New York Times, 2011, November 19, p. B1.

7. Sedláková, I., Tošner, J., Řezáč, A., a kol. Rezistence/senzitivita in vitro u pacientek s karcinomem ovaria. Čes Gynek, 2010, 3, s. 182–187.